Press Releases

Date Title  
Toggle Summary Aimmune Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
Presentation on Wednesday, January 11, 2017 , at 5:00 p.m. Pacific Time BRISBANE, Calif. --(BUSINESS WIRE)--Jan. 4, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization I mmuno T herapy) treatments for
Toggle Summary Aimmune Therapeutics Appoints Scientific Advisory Board of World-Renowned Food Allergy Experts
— Five Leading Food Allergy Researchers and Clinicians Form Distinguished Board — BRISBANE, Calif. --(BUSINESS WIRE)--Dec. 1, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization I mmuno T herapy) treatments for
Toggle Summary Aimmune Therapeutics Completes Global Enrollment of Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy
— Top-Line PALISADE Data Expected in 4Q 2017 — — New Clinical Study: ARTEMIS Dedicated European Pediatric Trial of AR101 Will Explore Protection at an Endpoint of Tolerating 2,043 mg of Peanut Protein after Nine Months of Treatment — BRISBANE, Calif. --(BUSINESS WIRE)--Nov.
Toggle Summary Aimmune Therapeutics Closes $145 Million Investment by Nestlé Health Science
BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 28, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization I mmuno T herapy) treatments for life-threatening food allergies, today announced the closing of the $145 million
Toggle Summary Aimmune Therapeutics to Host Investor Symposium Featuring Leading Experts in Peanut Allergy
BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 21, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization I mmuno T herapy) treatments for life-threatening food allergies, today announced that it will host an Investor
Toggle Summary Aimmune Therapeutics Announces Third Quarter 2016 Financial Results and Provides Corporate Update
BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 14, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization I mmuno T herapy) treatments for life-threatening food allergies, today announced financial results for the third
Toggle Summary Aimmune Therapeutics Announces $145 Million Equity Investment by Nestlé Health Science, Demonstrating Shared Commitment to Advancing Food Allergy Therapeutics
— Nestlé Health Science to Make Investment through the Purchase of Nearly 7.6 Million Shares of Aimmune Stock at $19.20 per Share — — Companies Enter into Strategic Collaboration Agreement Designed to Enable the Successful Development and Commercialization of Innovative Food Allergy Therapies — —
Toggle Summary Aimmune Therapeutics to Participate in Two Upcoming Investor Conferences
BRISBANE, Calif. --(BUSINESS WIRE)--Oct. 31, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization I mmuno T herapy) treatments for life-threatening food allergies, today announced that Stephen G.
Toggle Summary Aimmune Therapeutics to Participate in Two Upcoming Medical Meetings
BRISBANE, Calif. --(BUSINESS WIRE)--Oct. 11, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization I mmuno T herapy) treatments for life-threatening food allergies, today announced that it will present Phase 2 clinical
Toggle Summary Aimmune Therapeutics Completes and Exceeds North American Enrollment Target Ahead of Schedule in Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy; Company Accelerates Plans for Real-World Experience Study in the U.S.
— PALISADE Top-Line Results Expected in 4Q 2017 — — New RAMSES Real-World Experience Study, to Begin in 1Q 2017, Will Evaluate AR101 and Use of Potential Predictive Peanut-Specific Biomarkers Without Requiring an Oral Food Challenge for Study Entry — — Management to Host Conference Call at 5:00